Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Wednesday

Sagimet Biosciences (NASDAQ:SGMT) is anticipated to post its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Sagimet Biosciences to announce earnings of ($0.28) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.06. On average, analysts expect Sagimet Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sagimet Biosciences Stock Up 11.7%

SGMT opened at $7.99 on Wednesday. The firm has a 50 day moving average price of $7.15 and a 200-day moving average price of $6.40. Sagimet Biosciences has a twelve month low of $4.50 and a twelve month high of $10.06. The stock has a market capitalization of $260.31 million, a price-to-earnings ratio of -5.96 and a beta of 3.37.

Analyst Ratings Changes

Several equities research analysts recently issued reports on SGMT shares. Oppenheimer restated an “outperform” rating on shares of Sagimet Biosciences in a report on Friday, May 1st. Canaccord Genuity Group boosted their target price on shares of Sagimet Biosciences from $28.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Friday, July 17th. Guggenheim dropped their price target on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. Finally, Citizens Jmp cut their price objective on Sagimet Biosciences from $35.00 to $12.00 and set a “market outperform” rating for the company in a report on Tuesday, May 19th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.57.

Insiders Place Their Bets

In other Sagimet Biosciences news, insider Elizabeth Rozek sold 10,545 shares of Sagimet Biosciences stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $7.76, for a total transaction of $81,829.20. Following the transaction, the insider owned 224,414 shares of the company’s stock, valued at $1,741,452.64. The trade was a 4.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 18,844 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $7.46, for a total transaction of $140,576.24. Following the completion of the sale, the director directly owned 62,161 shares of the company’s stock, valued at approximately $463,721.06. This trade represents a 23.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 93,440 shares of company stock worth $719,441. Company insiders own 11.50% of the company’s stock.

Institutional Investors Weigh In On Sagimet Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC bought a new position in shares of Sagimet Biosciences in the first quarter worth about $105,000. Geode Capital Management LLC lifted its holdings in Sagimet Biosciences by 0.6% in the 2nd quarter. Geode Capital Management LLC now owns 265,324 shares of the company’s stock worth $2,023,000 after purchasing an additional 1,600 shares in the last quarter. American Century Companies Inc. boosted its stake in Sagimet Biosciences by 8.9% in the 2nd quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock worth $322,000 after purchasing an additional 3,454 shares during the period. XTX Topco Ltd raised its position in shares of Sagimet Biosciences by 137.0% during the second quarter. XTX Topco Ltd now owns 25,624 shares of the company’s stock valued at $195,000 after buying an additional 14,813 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in shares of Sagimet Biosciences in the second quarter worth $1,130,000. 87.86% of the stock is owned by institutional investors.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.